A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)

Trial Profile

A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARPEGGIO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 17 May 2018 According to an Active Biotech media release, data from this study were presented at the Annual Meeting of the American Academy of Neurology (AAN).
    • 27 Apr 2018 The primary efficacy analysis, as well as other efficacy and safety data will be presented. The anticipated date of database lock is November 8, 2017 as per trial design presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Trial design presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top